InvestorsHub Logo
Followers 33
Posts 2859
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Sunday, 07/11/2021 1:26:47 PM

Sunday, July 11, 2021 1:26:47 PM

Post# of 977
The company announces that it has dosed the first patient with 621, in combination with doxorubicin in a Phase I/II trial in leiomyosarcoma. It will enrol ~60 newly diagnosed patients, with primary endpoints being safety and ORR.